

Oncolytic Virus Cancer Therapy - Pipeline Insight, 2022

<https://marketpublishers.com/r/OBEFEDF16AB6EN.html>

Date: January 2022

Pages: 140

Price: US\$ 2,500.00 (Single User License)

ID: OBEFEDF16AB6EN

Abstracts

This report can be delivered to the clients within 2-3 Business Days

DelveInsight's, "Oncolytic Virus Cancer Therapy - Pipeline Insight, 2022" report provides comprehensive insights about 45+ companies and 85+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Oncolytic Virus Cancer Therapy Understanding

Oncolytic Virus Cancer Therapy: Overview

Oncolytic virus (OV) cancer therapies are the virus based therapeutic strategies that infect and destroy cancer cells, and therefore act as an in situ cancer vaccine by releasing tumor-specific antigens. Viruses such as myxoma virus or reovirus have inherent selectivity to tumor cells, while being nonpathogenic to healthy human cells. On the other hand, other OVs, including adenovirus, herpes simplex virus type-1 (HSV-1), and vesicular stomatitis virus (VSV), have been genetically engineered to function as vectors to boost anti-tumor immune responses. The therapeutic efficacy of Oncolytic viruses depends on two main modes of action: First, Oncolytic viruses can inhibit

protein synthesis of tumor cells and destroy infected tumor cells by self-replication. After viral infection, Oncolytic viruses continue self-replication until the cell bursts; Second, Oncolytic viruses can recruit and activate tumor-infiltrating immune cells by releasing a large amount of tumor antigens and secreting cytokines. Oncolytic virus cancer therapies can be used for diagnosis as well treatment of cancer. The anti-tumor efficacies of these OV's have been evaluated in many preclinical and clinical studies as monotherapy and combination therapy.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Oncolytic Virus Cancer Therapy R&D. The therapies under development are focused on novel approaches for Oncolytic Virus Cancer Therapy.

Oncolytic Virus Cancer Therapy Emerging Drugs Chapters

This segment of the Oncolytic Virus Cancer Therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Oncolytic Virus Cancer Therapy Emerging Drugs

CG0070: CG Oncolgy

CG0070 is an investigational oncolytic immunotherapy based on a modified common cold adenovirus backbone that contains a cancer-specific promoter and a GM-CSF transgene. CG0070, first replicates inside the tumor's cells causing tumor cell lysis and immunogenic cell death. Then, the rupture of the cancer cells can release tumor-derived antigens, along with GM-CSF, that can stimulate a systemic anti-tumor immune response that involves the body's own white blood cells. CG0070 is in development for a variety of solid tumor types to be used alone or in combination with immune checkpoint modulators. The therapy is in clinical development for the treatment of Bladder cancer and preclinical studies for solid tumors. In advanced clinical studies, CG0070 has been shown to be a safe and efficacious agent in NMIBC following BCG

failure.

ONCOS-102: Targovax

ONCOS-102 is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal malignancies and has shown promising clinical results both as monotherapy and in combination with chemotherapy, and a checkpoint inhibitor. In February 2021, Targovax announced that ONCOS-102 has received Fast-Track designation in malignant pleural mesothelioma from the US FDA.

Further product details are provided in the report.....

Oncolytic Virus Cancer Therapy: Therapeutic Assessment

This segment of the report provides insights about the different Oncolytic Virus Cancer Therapy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Oncolytic Virus Cancer Therapy

There are approx. 45+ key companies which are developing the Oncolytic Virus Cancer Therapy. The companies which have their Oncolytic Virus Cancer Therapy drug candidates in the most advanced stage, i.e. Phase III include, CG Oncolgy.

Phases

DelveInsight's report covers around 85+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Oncolytic Virus Cancer Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Oncolytic Virus Cancer Therapy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Oncolytic Virus Cancer Therapy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Oncolytic Virus Cancer Therapy drugs.

Oncolytic Virus Cancer Therapy Report Insights

Oncolytic Virus Cancer Therapy Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Oncolytic Virus Cancer Therapy Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Oncolytic Virus Cancer Therapy drugs?

How many Oncolytic Virus Cancer Therapy drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Oncolytic Virus Cancer Therapy?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Oncolytic Virus Cancer Therapy therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Oncolytic Virus Cancer Therapy and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

CG Oncolgy

Oncolytics Biotech

Astellas Pharma

DNAtrix

Nouscom

ImmVira Pharma

Targovax

Istari Oncology

SillaJen Biotherapeutics

Transgene

Advantagene

Wuhan Binhui Biotechnology

PsiOxus Therapeutics

VCN Biosciences

Vyriad

Oncolys Biopharma

Replimune

Oncorus

Key Products

CG0070

Pelareorep

ASP-9801

DNX 2440

NOUS PEV

T3011

ONCOS-102

PVS-RIPO

Pexa-Vec

Research programme: oncolytic vaccinia virus therapies

rQNestin 34.5

oHSV-2

Enadenotucirev

NG-348

NG-350A

NG-641

NG-347

NG-796A

VCN-01

Voyager-V1

TG6002

BT 001

Tasadenoturev

Suratadenoturev

RP1

OBP-702

ONCR-177

Contents

Introduction

Executive Summary

Oncolytic Virus Cancer Therapy: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Oncolytic Virus Cancer Therapy – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Oncolytic Virus Cancer Therapy companies' collaborations, Licensing, Acquisition

-Deal Value Trends

Oncolytic Virus Cancer Therapy Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

CG0070: CG Oncolgy

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Pelareorep: Oncolytics Biotech

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

ASP-9801: Astellas Pharma

Product Description

Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Pre-clinical and Discovery Stage Products
Comparative Analysis
Research programme: oncolytic vaccinia virus therapies - AstraZeneca/Transgene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
Comparative Analysis
Oncolytic Virus Cancer Therapy Key Companies
Oncolytic Virus Cancer Therapy Key Products
Oncolytic Virus Cancer Therapy- Unmet Needs
Oncolytic Virus Cancer Therapy- Market Drivers and Barriers
Oncolytic Virus Cancer Therapy- Future Perspectives and Conclusion
Oncolytic Virus Cancer Therapy Analyst Views
Oncolytic Virus Cancer Therapy Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Oncolytic Virus Cancer Therapy

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Oncolytic Virus Cancer Therapy

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Oncolytic Virus Cancer Therapy - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/OBEFEDF16AB6EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/OBEFEDF16AB6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970